Emerging treatments for retinopathy of prematurity
- PMID: 19373691
- PMCID: PMC4028623
- DOI: 10.1080/08820530902800322
Emerging treatments for retinopathy of prematurity
Abstract
Retinopathy or prematurity (ROP) is a leading cause of potentially preventable blindness in children. With increased survival of infants born at earlier gestational ages the number of infants at risk from vision loss from ROP has increased. Current treatments consist of close monitoring of oxygen saturation levels, peripheral retinal ablation by cryotherapy or laser photocoagulation, and vitreoretinal surgery. Research in the area of angiogenesis has lead to numerous breakthroughs. Emerging treatments for ROP are targeting the Vascular Endothelial Growth Factor (VEGF) and Insulin-Like Growth Factor 1 (IGF-1) pathways, as well as dietary supplementation with omega-3-polyunsaturated fatty acids.
Conflict of interest statement
Declaration of Interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
References
-
- Lutty GA, Chan-Ling T, Phelps DL, et al. Proceedings of the third international symposium on retinopathy of prematurity: An update on ROP from the lab to the nursery (November 2003, Anaheim, California) Mol Vis. 2006;12:532–580. - PubMed
-
- Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469–473. - PubMed
-
- Tasman W, Patz A, McNamara JA, et al. Retinopathy of prematurity: The life of lifetime disease. Am J Ophthalmol. 2006;141:167–174. - PubMed
-
- Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; A clinical approach. Med J Aust. 1951;2:48–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous